دورية أكاديمية
Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature.
| العنوان: | Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature. |
|---|---|
| المؤلفون: | Alaeikhanehshir S; Division of Molecular Pathology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Department of Surgical Oncology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Ajayi T; European Organisation for Research and Treatment of Cancer EORTC Headquarters, Brussels, Belgium., Duijnhoven FH; Department of Surgical Oncology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Poncet C; European Organisation for Research and Treatment of Cancer EORTC Headquarters, Brussels, Belgium., Olaniran RO; European Organisation for Research and Treatment of Cancer EORTC Headquarters, Brussels, Belgium., Lips EH; Division of Molecular Pathology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., van 't Veer LJ; Department of Laboratory Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA., Delaloge S; Department of Cancer Medicine, Gustave Roussy, Villejuif, France., Rubio IT; Breast Surgical Oncology, Clinica Universidad de Navarra, Madrid, Spain., Thompson AM; Dan L Duncan Comprehensive Cancer Centre, Baylor College of Medicine, Houston, TX., Cardoso F; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal., Piccart M; Department of Research, Jules Bordet Institute, Free University of Brussels, Brussels, Belgium., Rutgers EJT; Department of Surgical Oncology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. |
| المصدر: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Apr 01; Vol. 42 (10), pp. 1124-1134. Date of Electronic Publication: 2024 Jan 19. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2003- : Alexandria, VA : American Society of Clinical Oncology Original Publication: New York, N.Y. : Grune & Stratton, c1983- |
| مواضيع طبية MeSH: | Breast Neoplasms*/therapy , Breast Neoplasms*/drug therapy, Female ; Humans ; Combined Modality Therapy ; Mastectomy, Segmental/adverse effects ; Risk Factors ; Neoplasm Recurrence, Local/drug therapy ; Recurrence |
| مستخلص: | Purpose: A number of studies are currently investigating de-escalation of radiation therapy in patients with a low risk of in-breast relapses on the basis of clinicopathologic factors and molecular tests. We evaluated whether 70-gene risk score is associated with risk of locoregional recurrence (LRR) and estimated 8-year cumulative incidences for LRR in patients with early-stage breast cancer treated with breast conservation. Methods: In this exploratory substudy of European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT trial, we evaluated women with a known clinical and genomic 70-gene risk score test result and who had breast-conserving surgery (BCS). The primary end point was LRR at 8 years, estimated by cumulative incidences. Distant metastasis and death were considered competing risks. Results: Among 6,693 enrolled patients, 5,470 (81.7%) underwent BCS, of whom 98% received radiotherapy. At 8-year follow-up, 189 patients experienced a LRR, resulting in an 8-year cumulative incidence of 3.2% (95% CI, 2.7 to 3.7). In patients with a low-risk 70-gene signature, the 8-year LRR incidence was 2.7% (95% CI, 2.1 to 3.3). In univariable analysis, adjusted for chemotherapy, five of 12 variables were associated with LRR, including the 70-gene signature. In multivariable modeling, adjuvant endocrine therapy and to a lesser extent tumor size and grade remained significantly associated with LRR. Conclusion: This exploratory analysis of the MINDACT trial estimated an 8-year low LRR rate of 3.2% after BCS. The 70-gene signature was not independently predictive of LRR perhaps because of the low number of events observed and currently cannot be used in clinical decision making regarding LRR. The overall low number of events does provide an opportunity to design trials toward de-escalation of local therapy. |
| سلسلة جزيئية: | ClinicalTrials.gov NCT00433589 |
| تواريخ الأحداث: | Date Created: 20240119 Date Completed: 20240329 Latest Revision: 20240329 |
| رمز التحديث: | 20240329 |
| DOI: | 10.1200/JCO.22.02690 |
| PMID: | 38241603 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1527-7755 |
|---|---|
| DOI: | 10.1200/JCO.22.02690 |